Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.61 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.49 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950789 | 0.80 | EGLN1 (0.53) | EGLN1FTOEGLN2BBOX1EGLN3 | |
| SCHEMBL821293 | 0.76 | EGLN1 (0.68) | EGLN1FTOEGLN2BBOX1EGLN3 | |
| SCHEMBL31501044 | 0.76 | EGLN1 (0.68) | EGLN1FTOEGLN2BBOX1EGLN3 | |
| SCHEMBL1269062 | 0.76 | EGLN1 (0.64) | EGLN1FTOBBOX1 | |
| SCHEMBL2298401 | 0.74 | EGLN1 (0.40) | EGLN1 | |
| SCHEMBL966315 | 0.74 | EGLN1 (0.56) | EGLN1FTOEGLN2BBOX1EGLN3 | |
| SCHEMBL522880 | 0.73 | EGLN1 (0.73) | EGLN1FTOEGLN2BBOX1EGLN3 | |
| SCHEMBL522834 | 0.73 | EGLN1 (0.58) | EGLN1FTOEGLN2BBOX1EGLN3 | |
| SCHEMBL14649383 | 0.73 | EGLN1 (0.73) | EGLN1FTOEGLN2BBOX1EGLN3 | |
| SCHEMBL12502853 | 0.73 | EGLN1 (1.00) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | EGLN1 238/4885FTO 4088/4885EGLN2 215/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | EGLN1 1148/4885FTO 4102/4885EGLN2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.